Intervention
Omarigliptin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 16 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
16 shownReal-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNCT06449235 · 2024-09-01
UNKNOWNOmarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)NCT02906709 · 2016-10-17
COMPLETEDA Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)NCT01863667 · 2013-07-08
TERMINATEDStudy to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)NCT01841697 · 2013-06-13
COMPLETEDA Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)NCT01814748 · 2013-05-03
COMPLETEDA Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)NCT01755156 · 2013-01-11
COMPLETEDA Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)NCT01717313 · 2012-12-05
COMPLETEDOmarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)NCT01703221 · 2012-10-24
COMPLETEDOmarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)NCT01697592 · 2012-10-24
COMPLETEDAddition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)NCT01704261 · 2012-10-18
COMPLETEDA Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)NCT01703208 · 2012-10-05
TERMINATEDA Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)NCT01698775 · 2012-10-02
COMPLETEDA Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)NCT01682759 · 2012-09-10
COMPLETEDA Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)NCT01407276 · 2011-08-08
COMPLETEDA Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)NCT01217073 · 2010-10-08
COMPLETEDEvaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)NCT01088711 · 2010-03-11
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED13
TERMINATED2
UNKNOWN1
Phase mix
PHASE311
PHASE12
PHASE42
PHASE21
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.